İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2022 · article

The significance of a novel inflammatory biomarker, presepsin, in predicting disease prognosis in patients with COVID-19

YÖKSİS OpenAlex
Yıl2022
Atıf4OpenAlex
Yüzdelik%59,6
FWCI0,391,00 = dünya ortalaması
Scopus (SJR)Q2
WoS (JCR)Q2

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıEuropean Review for Medical and Pharmacological Sciences
  • Katalog eşleşmesi (ISSN)European Review for Medical and Pharmacological Sciences (discontinued)
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

OBJECTIVE: This study aims at determining the significance of a novel inflammatory biomarker, presepsin, in predicting disease prognosis in patients with COVID-19. PATIENTS AND METHODS: This retrospective study was concluded at the University Hospital between April and August 2020. The study involved 88 COVID-19 patients (48 men and 40 women). The patients were categorized into two groups: the patients admitted to the COVID-19 clinic, described as the moderate COVID-19 patients (Group-1; n=44), and those admitted to the internal medicine outpatient clinic, who were the mild COVID-19 patients (Group-2; n=44). The groups were compared using inflammatory markers: presepsin, C-Reactive Protein to Albumin Ratio, Neutrophil to Lymphocyte Ratio, and procalcitonin. RESULTS: Serum presepsin levels (195.29 vs. 52.12 pg/ml) were significantly higher in the Group-1 compared to the Group-2 (p=0.001). The gender distribution and average age were similar in both groups (p > 0.05). While ferritin, lactate dehydrogenase, D-Dimer, platelet lymphocyte ratio, C-Reactive Protein to Albumin Ratio (p=0.001), erythrocyte sedimentation ratio, C-Reactive Protein and presepsin were significantly higher in the Group-1 compared to Group-2 (p<0.05), while hemoglobin and lymphocyte were significantly lower in the Group-1 than in Group-2 (p<0.05). CONCLUSIONS: Serum presepsin levels were found to be significantly higher in moderate clinical group COVID-19 patients compared to mild group. Presepsin, a new inflammatory biomarker, may be useful in predicting the prognosis and early treatment of COVID-19 infection.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

4atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yazarlar

14
  1. CENGİZ KARACAER 1
  2. H Sert 2
  3. T Demirci 3
  4. C Varım 4
  5. G Kaya 5
  6. A B Genc 6
  7. D Cekic 7
  8. HASAN ERGENÇ 8
  9. ZEYNEP ERGENÇ YALOVA ÜNİVERSİTESİ 9
  10. S Yaylacı 10
  11. A Nalbant 11
  12. T Kaya 12
  13. A Demirci 13
  14. K E Oztop 14